Results from HSPPC-96 Phase 2 study against recurrent gliobastoma presented at ASCO 2
 

In data presented at The American Society of Clinical Oncology (ASCO) Annual Meeting, cancer researchers found that the brain tumor vaccine HSPPC-96 for treating recurrent gliobastoma (GBM) has a favorable safety profile and extends survival by two to three times more than the current median survival rate.

More...